Have a personal or library account? Click to login
A dynamic stopping rule for phase I clinical trials Cover

A dynamic stopping rule for phase I clinical trials

Open Access
|Jun 2018

Abstract

This paper investigates a stopping rule to be utilised in phase I clinical trials. The motivation is to develop a dynamic rule so that a trial stops early if the maximum tolerated dose lies towards the beginning of a dose region. Also, it will employ many patients if the maximum tolerated dose lies towards the end of a dose region. A two-parameter logistic model is assumed for the dose-response data. A trial is stopped early before reaching the maximum number of patients when the width of the Bayesian posterior probability interval of the slope parameter meets a desired value. Instead of setting a pre-specified width to stop at, we determine it based on the parameter estimate obtained after a reasonable number of steps in a trial. Simulation studies of six plausible dose-response scenarios show that the proposed stopping rule is capable of limiting the number of patients to be recruited depending on the underlying scenario. Although the rule is applied to a D-optimum design here, it will be equally applicable to other model-based designs.

DOI: https://doi.org/10.2478/bile-2018-0002 | Journal eISSN: 2199-577X | Journal ISSN: 1896-3811
Language: English
Page range: 17 - 30
Published on: Jun 22, 2018
Published by: Polish Biometric Society
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year

© 2018 M. Iftakhar Alam, Mohaimen Mansur, published by Polish Biometric Society
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.